LAUSR

Type 2 Diabetes is somewhat of a global epidemic, where more than 422 million people worldwide are living with diabetes over the age of 18. It is evident that a product to target such a non-communicable disease is necessary as a means to improve these statistics. At present, through a previous glucose study carried out by Food for Health Ireland, it is known that 12 g of a milk hydrolysate effectively reduces the post-prandial glycaemic response, through the action of insulin. However, due to the high level of bitterness and the high cost of such hydrolysates, it is important to reduce the required dose while still maintaining efficacy, in order to allow for successful incorporation into food products. The aim of the present study was to establish a minimum dose of the milk hydrolysate that would effectively reduce the glycaemic response after a standardised breakfast, compared to 12 g of the milk hydrolysate in a healthy male cohort. Participants (n 13) came to UCD to trial 4 different doses of the milk hydrolysate: 12 g, 9 g, 6 g and a control (0 g). Plasma and serum samples were taken at fifteen-minute intervals for the first hour, and thirty-minute intervals for the second hour of each visit. Serum insulin was analysed using the human insulin ELISA kit (Mercodia, Sweden). Plasma glucose was measured using the Randox clinical chemistry analyser (Randox Laboratories Ltd. United Kingdom). Differences in glucose and insulin concentrations were determined through one-way ANOVA analysis (SPSS 20·0·0).